A wholesale distribution authorisation (WDA) is granted by one country's authority for premises on that country's territory. A company that distributes medicines from both Belgium and the Netherlands therefore has two authorisations, two applications and two authorities to deal with. What it is inspected against is the same in both: the EU Good Distribution Practice (GDP) Guidelines.
The short answer
- Same standard. Both countries inspect against the EU GDP Guidelines (2013/C 343/01) (opens in a new tab) and require a named Responsible Person and a working quality system.
- Different authority and route. In Belgium the FAMHP grants the authorisation. In the Netherlands the application goes through Farmatec, with the IGJ (the Dutch Health and Youth Care Inspectorate) advising and supervising.
- Different national rules. The legal basis, the forms and some national roles differ. The Responsible Person for Information and Publicity (RIP), for example, is a Belgian role.
What is the same
The legal frame comes from EU law: Directive 2001/83/EC (opens in a new tab) requires an authorisation to act as a wholesaler of medicines, tied to the premises in the country that grants it. Beyond that, the two systems rest on the same building blocks:
- The EU GDP Guidelines set the quality system, premises, documentation, transport and complaints expectations, and section 2.2 sets out the responsibilities of the Responsible Person.
- The authorisation names the activities and the site, and the company's activities have to stay within them.
- Inspections follow the chapters of the GDP Guidelines, and GDP certificates are published in the EudraGMDP database (opens in a new tab).
Where they differ
| Topic | Belgium | Netherlands |
|---|---|---|
| Who grants and supervises | The FAMHP (opens in a new tab) (FAGG in Dutch, AFMPS in French) | Application through Farmatec (opens in a new tab), with advice and supervision from the IGJ (opens in a new tab) |
| Main legal basis | Article 12ter of the Medicines Act of 25 March 1964 and Articles 90 to 99 of the Royal Decree of 14 December 2006 (opens in a new tab) (Dutch) | The Geneesmiddelenwet (Dutch Medicines Act), chapter 3, with its implementing rules |
| Responsible Person | Named in the application, under Belgian eligibility, presence and notification rules | Named in the application, with the IGJ's published GDP questions and answers describing what it expects |
| Responsible Person for Information and Publicity (RIP) | A Belgian role linked to medicines information and advertising | Not a Dutch role |
| Language of the process | Forms and guidance in Dutch, French and, in part, English | Forms and guidance in Dutch |
What this means in practice
- Plan one application per country. Each names its own Responsible Person and its own premises.
- Keep one quality system, with local evidence. A group procedure can serve both countries, but each authority will want to see it applied at the premises it covers.
- Do not carry roles across the border. A Belgian RIP does not exist in the Dutch system, and a Responsible Person is appointed for a specific authorisation.
- Check the source for the authority you are dealing with. Forms and requirements are updated on the FAMHP, Farmatec and IGJ sites.
Where MEDCOR can help
For Belgian authorisations we prepare applications and changes, build GDP quality systems and can act as the named Responsible Person or as RIP. For Dutch wholesale authorisations our offer is the named Responsible Person appointment. See our pages on the Responsible Person for a Belgian WDA and the Responsible Person for a Dutch WDA, or send us the outline of your project.

